<DOC>
	<DOCNO>NCT00171860</DOCNO>
	<brief_summary>The objective study : 1 . Evaluation safety profile imatinib mesylate patient idiopathic hypereosinophilic syndrome resistant refractory , intolerant , prednisone , hydroxyurea interferon-alpha , untreated patient carry Fip1L1-PDGFRA fusion protein . 2 . Evaluation efficacy imatinib mesylate patient idiopathic hypereosinophilic syndrome 3 . Analysis patient 's blood sample detection activate kinase .</brief_summary>
	<brief_title>A Study Determine Safety Efficacy Imatinib Mesylate Patients With Idiopathic Hypereosinophilic Syndrome</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Hypereosinophilic Syndrome</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<criteria>Idiopathic hypereosinophilic syndrome include provide belong one follow category : 1. previously treat showing document resistance refractoriness , intolerance , prednisone , hydroxyurea interferonalpha . 2. previously treat documented Fip1L1PDGFRA fusion protein Other disease associate hypereosinophilia Serum creatinine , serum bilirubin , AST , ALT twice upper normal limit . ECOG performance status &gt; 3 Other protocoldefined exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>Hypereosinophilic syndrome</keyword>
	<keyword>Imatinib</keyword>
</DOC>